Translational Virology

SARS-CoV-2

Development of ELISAs and cell based neutralization assays, PRNT and MNT for SARS CoV-2 in record time by scientists from Communicable diseases turned to be a concrete research and development support to NIBEC, the entity which caters immunogenicity testing service to vaccine manufacturers.
Our group contributed to the understanding of pathophysiology of SARS CoV-2 infection in following areas
- Molecular and genetic characterization of SARS-CoV-2 (Wild type, Delta, Omicron etc)
- Humoral immune response (PRNT titers, IgA, IgG & Subclasses)
- Innate and Adaptive Cellular immune response (T cells, B cells, Dendritic cells, Macrophages, Neutrophils etc.)
We attempted to evaluate the real world data for cellular and humoral immune responses elicited by COVID vaccines towards its protective nature against recurrent infection and variants of concern (VOCs).